摘要
[目的]研究血清VEGFR-2浓度变化与肝癌患者经肝动脉化疗栓塞术(TACE)治疗后近期疗效的相关性。[方法]采用ELISA方法检测24例晚期肝癌患者TACE治疗前后血清VEGFR-2的表达水平,并分析VEGFR-2浓度变化与晚期肝癌患者临床病理的关系。[结果 ]血清VEGFR-2浓度与肿瘤数目、肝硬化病史有关(P<0.05);PFS与肿瘤数目、门脉癌栓、肿瘤大小、肝硬化有关(P<0.05)。治疗1个月后疾病缓解5例,疾病稳定14例,疾病进展5例,m PFS分别为7.84、4.78、3.68个月(P<0.05)。[结论]TACE术后1个月血清VEGFR-2浓度变化与PFS有关,血清VEGFR-2浓度变化可能成为肝癌TACE治疗潜在的近期疗效预测指标。
[Purpose] To study the correlation between the changes of serum VEGFR-2 concentration and short-term effects of hepatocellular carcinoma after transcatheter arterial chemoemboliza-tion. [Methods] Serum VEGF-2 expression level,measured by quatitative sandwich enzyme-linked immunosorbentassay（ELISA）,was measured before TACE 1 day and 1 month after TACE in 24 patients with HCC and the correlation between the change of VEGFR-2 concentration and clinical pathological characteristics of patients with advanced hepatocellular carcinoma was analyzed.[Results] The serum VEGFR-2 concentration was significantly correlated with the tumor size and hepatic cirrhosis（P〈0.05）. The progress free survival（PFS） was significantly correlated with the tumor size,portal vein invasion,tumer number and hepatic cirrhosis（P〈0.05）. There were 5 patients with partial response after one month of treatment,14 patients with stable disease,5 patients with progressive disease. The PFS was 7.84,4.71 and 3.68 months,respectively（P〈0.05）. [Conclusion]The change of serum VEGFR-2 concentration in early stage is related to PFS and VEGFR-2 may be a potential indicator for predicting the short-term effects of TACE in hepatocellular carcinoma.
作者
陈丹
王凯冰
李加桩
隋红
CHEN Dan WANG Kai-bing LI Jia-zhuang et al.(The Affiliated Tumour Hospital of Harbin Medical University,Harbin 150040,China The Second Hospital Affiliated to Harbin Medical University, Harbin 150086, China)
出处
《中国肿瘤》
CAS
CSCD
2017年第6期476-481,共6页
China Cancer
基金
吴阶平医学基金会临床科研专项资助基金(320.6750.15179)
